Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway
Cellular and Molecular Biology · 2024
DOI: 10.14715/cmb/2024.70.2.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular and Molecular Biology, 2024. Verfasst von Tiaohao Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanx…. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, MicroRNAs, Saponins, Triterpenes. Die Arbeit wurde bisher 18-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
As the main active ingredient of Astragalus, Astragaloside IV (AS-IV) can ameliorate pulmonary fibrosis. In this experiment, we studied how AS-IV reduces idiopathic pulmonary fibrosis (IPF). Bleomycin (BLM) or TGF-β1 was treated in mice or alveolar epithelial cells to mimic IPF in vivo as well as in vitro. ASV-IV alleviated levels of inflammatory cytokines and fibrosis markers in IPF model. Through detection of autophagy-related genes, ASV-IV was observed to induce autophagy in IPF. Besides, ASV-IV inhibited miR-21 expression in IPF models, and overexpression of miR-21 could reverse the protective potential of ASV-IV on IPF. PTEN was targeted by miR-21 and was up-regulated by ASV-IV in IPF models. In addition, levels of inflammatory cytokines and fibrosis markers, autophagy, as well as the PI3K/AKT/mTOR pathway regulated by ASV-IV could be neutralized after treatment with autophagy inhibitors, miR-21 mimics, or si-PTEN. Our study demonstrates that ASV-IV inhibits IPF through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway, suggesting that ASV-IV could be acted to be a promising therapeutic method for IPF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China. liboyu2009113@163.com.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China. szefyhxk@163.com.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China. jr1033800165@126.com.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China. s15769102749@163.com.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China. dingyeli110@163.com.
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an, Shaanxi, China. qwaszxeryu@163.com.
Zitieren
APA
Li, T., Gao, X., Jia, R., Sun, Y., Ding, Y., Wang, F., & Wang, Y. (2024). Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway. Cellular and Molecular Biology. https://doi.org/10.14715/cmb/2024.70.2.18
Vancouver
Li T, Gao X, Jia R, Sun Y, Ding Y, Wang F, et al. Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway. Cellular and Molecular Biology. 2024. doi:10.14715/cmb/2024.70.2.18
BibTeX
@article{Li2024,
author = {Li, Tiaohao and Gao, Xiaojuan and Jia, Rui and Sun, Yanling and Ding, Yeli and Wang, Fei and Wang, Yujuan},
title = {Astragaloside IV inhibits idiopathic pulmonary fibrosis through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway},
journal = {Cellular and Molecular Biology},
year = {2024},
doi = {10.14715/cmb/2024.70.2.18}
}
EUVIMED